PLC Medical Systems, Inc. is developing RenalGuard™ with a team of physicians and engineers with the objective of providing a solution to the complex challenge of Contrast-Induced Nephropathy, a form of Acute Renal Failure. It is a novel, yet simple approach aiming to advance the care of patients with renal-insufficiency undergoing imaging procedures.

What is CIN? Contrast-Induced Nephropathy (CIN) is a form of Acute Renal Failure caused by exposure to contrast media during image-guided cardiology and radiology procedures. The lack of effective treatment to prevent CIN remains problematic for patients with renal-insufficiency.

Our Solution RenalGuard Therapy™ is designed to reduce the toxic effects that contrast media can have on the kidneys for patients undergoing imaging procedures. This therapy is based on the theory that creating and maintaining a high urine output allows the body to rapidly eliminate contrast, reducing its toxic effects.

RenalGuard™ is presently undergoing Clinical Investigations and is therefore not yet commercially available.

This site contains medical information that is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns.